Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Long, Georgina V, MD, Stroyakovskiy, Daniil, MD, Gogas, Helen, MD, Levchenko, Evgeny, MD, de Braud, Filippo, MD, Larkin, James, FRCP, Garbe, Claus, Prof, Jouary, Thomas, MD, Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Chiarion-Sileni, Vanna, MD, Lebbe, Celeste, Prof, Mandalà, Mario, MD, Millward, Michael, Prof, Arance, Ana, MD, Bondarenko, Igor, Prof, Haanen, John B A G, Prof, Hansson, Johan, Prof, Utikal, Jochen, Prof, Ferraresi, Virginia, MD, Kovalenko, Nadezhda, Prof, Mohr, Peter, MD, Probachai, Volodymr, MD, Schadendorf, Dirk, Prof, Nathan, Paul, MD, Robert, Caroline, MD, Ribas, Antoni, Prof, DeMarini, Douglas J, PhD, Irani, Jhangir G, MA, Swann, Suzanne, PhD, Legos, Jeffrey J, PhD, Jin, Fan, MD, Mookerjee, Bijoyesh, MD, Flaherty, Keith, MD
Published in The Lancet (British edition) (01.08.2015)
Published in The Lancet (British edition) (01.08.2015)
Get full text
Journal Article
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Eggermont, Alexander M M, Prof, Chiarion-Sileni, Vanna, MD, Grob, Jean-Jacques, Prof, Dummer, Reinhard, Prof, Wolchok, Jedd D, MD, Schmidt, Henrik, MD, Hamid, Omid, MD, Robert, Caroline, Prof, Ascierto, Paolo A, Prof, Richards, Jon M, MD, Lebbé, Céleste, Prof, Ferraresi, Virginia, MD, Smylie, Michael, MD, Weber, Jeffrey S, MD, Maio, Michele, MD, Konto, Cyril, MD, Hoos, Axel, MD, de Pril, Veerle, MSc, Gurunath, Ravichandra Karra, MD, de Schaetzen, Gaetan, PhD, Suciu, Stefan, PhD, Testori, Alessandro, MD
Published in The lancet oncology (01.05.2015)
Published in The lancet oncology (01.05.2015)
Get full text
Journal Article
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Ascierto, Paolo A, Dr, Del Vecchio, Michele, MD, Robert, Caroline, Prof, Mackiewicz, Andrzej, Prof, Chiarion-Sileni, Vanna, MD, Arance, Ana, MD, Lebbé, Céleste, Prof, Bastholt, Lars, MD, Hamid, Omid, MD, Rutkowski, Piotr, Prof, McNeil, Catriona, MD, Garbe, Claus, Prof, Loquai, Carmen, MD, Dreno, Brigitte, Prof, Thomas, Luc, Prof, Grob, Jean-Jacques, Prof, Liszkay, Gabriella, Prof, Nyakas, Marta, MD, Gutzmer, Ralf, Prof, Pikiel, Joanna, MD, Grange, Florent, MD, Hoeller, Christoph, MD, Ferraresi, Virginia, MD, Smylie, Michael, MD, Schadendorf, Dirk, Prof, Mortier, Laurent, Prof, Svane, Inge Marie, MD, Hennicken, Delphine, MSc, Qureshi, Anila, MD, Maio, Michele, MD
Published in The lancet oncology (01.05.2017)
Published in The lancet oncology (01.05.2017)
Get full text
Journal Article
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
Gronchi, Alessandro, Dr, Ferrari, Stefano, MD, Quagliuolo, Vittorio, MD, Broto, Javier Martin, MD, Pousa, Antonio Lopez, MD, Grignani, Giovanni, MD, Basso, Umberto, MD, Blay, Jean-Yves, Prof, Tendero, Oscar, MD, Beveridge, Robert Diaz, MD, Ferraresi, Virginia, MD, Lugowska, Iwona, MD, Merlo, Domenico Franco, MD, Fontana, Valeria, MSc, Marchesi, Emanuela, MSc, Donati, Davide Maria, MD, Palassini, Elena, MD, Palmerini, Emanuela, MD, De Sanctis, Rita, MD, Morosi, Carlo, MD, Stacchiotti, Silvia, MD, Bagué, Silvia, MD, Coindre, Jean Michelle, Prof, Dei Tos, Angelo Paolo, Prof, Picci, Piero, MD, Bruzzi, Paolo, MD, Casali, Paolo Giovanni, MD
Published in The lancet oncology (01.06.2017)
Published in The lancet oncology (01.06.2017)
Get full text
Journal Article
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
Grignani, Giovanni, Dr, Palmerini, Emanuela, MD, Ferraresi, Virginia, MD, D'Ambrosio, Lorenzo, MD, Bertulli, Rossella, MD, Asaftei, Sebastian Dorin, MD, Tamburini, Angela, MD, Pignochino, Ymera, PhD, Sangiolo, Dario, PhD, Marchesi, Emanuela, PhD, Capozzi, Federica, BSc, Biagini, Roberto, MD, Gambarotti, Marco, MD, Fagioli, Franca, MD, Casali, Paolo Giovanni, MD, Picci, Piero, MD, Ferrari, Stefano, MD, Aglietta, Massimo, Prof
Published in The lancet oncology (01.01.2015)
Published in The lancet oncology (01.01.2015)
Get full text
Journal Article
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
Coens, Corneel, MSc, Suciu, Stefan, PhD, Chiarion-Sileni, Vanna, MD, Grob, Jean-Jacques, Prof, Dummer, Reinhard, Prof, Wolchok, Jedd D, MD, Schmidt, Henrik, MD, Hamid, Omid, MD, Robert, Caroline, Prof, Ascierto, Paolo A, Prof, Richards, Jon M, MD, Lebbé, Celeste, Prof, Ferraresi, Virginia, MD, Smylie, Michael, MD, Weber, Jeffrey S, MD, Maio, Michele, MD, Bottomley, Andrew, PhD, Kotapati, Srividya, PharmD, de Pril, Veerle, Testori, Alessandro, MD, Eggermont, Alexander M M, Prof
Published in The lancet oncology (01.03.2017)
Published in The lancet oncology (01.03.2017)
Get full text
Journal Article